Xencor (XNCR) Receivables - Other (2016 - 2024)
Xencor (XNCR) posted quarterly Receivables - Other of $5.7 million for Q4 2024, up 147.83% year-over-year from $2.3 million in Q1 2024, and up 147.83% quarter-over-quarter from $2.3 million in Q4 2023.
Xencor (XNCR) Receivables - Other (2016 - 2024) Analysis & Trends
Xencor (XNCR) has reported Receivables - Other for 8 consecutive years, with $5.7 million the latest figure, recorded in Q4 2024.
- In Q4 2024, Receivables - Other rose 147.83% year-over-year to $5.7 million; the TTM figure through Dec 2024 stood at $5.7 million (up 147.83% YoY), while the FY2024 annual figure was $5.7 million, up 147.83% from the prior year.
- Receivables - Other advanced to $5.7 million in Q4 2024 per XNCR's latest filing, from $2.3 million in the prior quarter.
- Across five years, Receivables - Other topped out at $12.5 million in Q1 2021 and bottomed at $500000.0 in Q2 2021.
- Historically, Receivables - Other has averaged $3.7 million across 5 years, with a median of $1.8 million in 2020.
- Annual changes were most pronounced in 2022 — Receivables - Other plunged 60.0% — and 2024, when it surged 147.83%.
- Xencor's Receivables - Other stood at $1.4 million in 2020, then plunged by 42.86% to $800000.0 in 2021, then jumped by 62.5% to $1.3 million in 2022, then soared by 76.92% to $2.3 million in 2023, then soared by 147.83% to $5.7 million in 2024.
- Business Quant data shows XNCR's Receivables - Other at $5.7 million in Q4 2024, $2.3 million in Q4 2023, and $1.3 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Xencor | 1.73 Bn | 1.36 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 5.70 Mn |
| Dec 31, 2024 | 5.70 Mn |
| Dec 31, 2023 | 2.30 Mn |
| Dec 31, 2023 | 2.30 Mn |
| Dec 31, 2022 | 1.30 Mn |
| Dec 31, 2022 | 1.30 Mn |
| Mar 31, 2022 | 5.00 Mn |
| Mar 31, 2022 | 5.00 Mn |
| Dec 31, 2021 | 800,000.00 |
| Dec 31, 2021 | 800,000.00 |
| Jun 30, 2021 | 500,000.00 |
| Jun 30, 2021 | 500,000.00 |
| Mar 31, 2021 | 12.50 Mn |
| Mar 31, 2021 | 12.50 Mn |
| Dec 31, 2020 | 1.40 Mn |
| Dec 31, 2020 | 1.40 Mn |
| Dec 31, 2019 | 2.70 Mn |
| Dec 31, 2019 | 2.70 Mn |
| Mar 31, 2017 | 2.34 Mn |
| Mar 31, 2017 | 2.34 Mn |